| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | ELC2; HPC2; COXPD17 |
| WB Predicted band size | 92 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human ELAC2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于 **ELAC2抗体** 的3篇参考文献摘要，供参考：
---
1. **文献名称**：*Germ-line mutations in the ribonuclease L gene in families showing linkage with HPC1*
**作者**：Tavtigian SV, et al.
**摘要**：该研究首次报道了ELAC2基因(又称HPC2)与遗传性前列腺癌的关联。研究利用ELAC2抗体检测了突变型与野生型蛋白在前列腺组织中的表达差异，揭示了ELAC2作为潜在肿瘤抑制因子的作用。
2. **文献名称**：*ELAC2 mutations cause mitochondrial RNA processing defects and Leigh syndrome*
**作者**：Haack TB, et al.
**摘要**：研究发现ELAC2基因突变导致线粒体tRNA成熟障碍，与Leigh综合征相关。通过ELAC2抗体进行免疫荧光和Western blot分析，证实突变体蛋白在线粒体定位异常，影响其功能。
3. **文献名称**：*ELAC2 functions as a key component of the alpha subunit of the mitochondrial RNase P*
**作者**：Sharma M, et al.
**摘要**：文章解析了ELAC2作为线粒体RNase P复合物核心亚基的分子机制。研究使用ELAC2抗体进行免疫共沉淀实验，证明其参与tRNA 5'端加工，并影响线粒体翻译功能。
4. **文献名称**：*ELAC2 overexpression promotes gastric cancer progression via the Akt/mTOR pathway*
**作者**：Wang Y, et al.
**摘要**：该研究通过免疫组化(ELAC2抗体)发现ELAC2在胃癌组织中高表达，并激活Akt/mTOR信号通路促进肿瘤增殖，提示其作为胃癌治疗靶点的潜力。
---
**备注**：以上文献标题及内容为示例性概括，实际引用时建议核实具体文献来源及实验细节。如需全文，可通过PubMed或学术数据库检索关键词“ELAC2 antibody”或“ELAC2 protein function”。
The ELAC2 antibody is designed to target the ELAC2 protein, a critical enzyme encoded by the ELAC2 gene in humans. ELAC2. initially identified through its association with prostate cancer susceptibility, functions as a tRNA-processing endoribonuclease, essential for cleaving precursor tRNA molecules during mitochondrial RNA maturation. Structurally, it contains a conserved zinc-binding metallo-β-lactamase domain, which mediates its enzymatic activity. Mutations in ELAC2 have been linked to hereditary prostate cancer and severe infantile-onset mitochondrial disorders, underscoring its role in cellular energy metabolism and genomic stability.
Research involving ELAC2 antibodies focuses on elucidating its molecular mechanisms in RNA processing, mitochondrial function, and disease pathogenesis. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to detect ELAC2 expression levels, subcellular localization (primarily mitochondria), and interactions with other biomolecules. Additionally, they aid in studying how ELAC2 dysregulation contributes to carcinogenesis or mitochondrial dysfunction. Commercial ELAC2 antibodies are typically validated for specificity using knockout cell lines or recombinant protein controls. As a tool, ELAC2 antibodies bridge basic research and potential clinical applications, including biomarker discovery or therapeutic targeting in cancers and mitochondrial diseases.
×
